company background image

GemVax&KAELLtd KOSDAQ:A082270 Stock Report

Last Price


Market Cap







04 Oct, 2022


Company Financials
A082270 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health4/6

A082270 Stock Overview

GemVax&KAEL Co.,Ltd engages in the manufacturing and commercializing of resins and filters for semi-conductor and panel display production in South Korea.

Risk Analysis

No risks detected for A082270 from our risk checks.

GemVax&KAELLtd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GemVax&KAELLtd
Historical stock prices
Current Share Price₩12,700.00
52 Week High₩20,500.00
52 Week Low₩11,550.00
1 Month Change-3.05%
3 Month Change-2.68%
1 Year Change-34.03%
3 Year Change5.83%
5 Year Change13.90%
Change since IPO63.03%

Recent News & Updates

Apr 03
GemVax&KAELLtd's (KOSDAQ:082270) Earnings Are Weaker Than They Seem

GemVax&KAELLtd's (KOSDAQ:082270) Earnings Are Weaker Than They Seem

GemVax&KAEL Co.,Ltd ( KOSDAQ:082270 ) announced strong profits, but the stock was stagnant. We did some digging, and we...

Feb 17
Is GemVax&KAELLtd (KOSDAQ:082270) A Risky Investment?

Is GemVax&KAELLtd (KOSDAQ:082270) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Shareholder Returns

A082270KR SemiconductorKR Market

Return vs Industry: A082270 underperformed the KR Semiconductor industry which returned -23.6% over the past year.

Return vs Market: A082270 underperformed the KR Market which returned -29% over the past year.

Price Volatility

Is A082270's price volatile compared to industry and market?
A082270 volatility
A082270 Average Weekly Movement5.0%
Semiconductor Industry Average Movement6.2%
Market Average Movement5.9%
10% most volatile stocks in KR Market10.6%
10% least volatile stocks in KR Market3.6%

Stable Share Price: A082270 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: A082270's weekly volatility (5%) has been stable over the past year.

About the Company

1998170Sang-Jae Kim

GemVax&KAEL Co.,Ltd engages in the manufacturing and commercializing of resins and filters for semi-conductor and panel display production in South Korea. The company offers impregnated active carbon and inorganic adsorbent coating resins; CA filter for removing chemical pollution substances and harmful gases in semiconductor and LCD/PDP manufacturing process; adsorbent towers for air pollution prevention; and pressure facility for preventing equipment erosion within a substation; and 5aver, a fire evacuation mask. It also engages in the research and development of anti-cancer immunotherapeutic and peptide drugs; and provides RIAVAX, an immunotherapeutic peptide for the treatment of locally advanced or metastatic pancreatic cancer.

GemVax&KAELLtd Fundamentals Summary

How do GemVax&KAELLtd's earnings and revenue compare to its market cap?
A082270 fundamental statistics
Market Cap₩498.30b
Earnings (TTM)-₩424.56m
Revenue (TTM)₩71.87b


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A082270 income statement (TTM)
Cost of Revenue₩50.81b
Gross Profit₩21.06b
Other Expenses₩21.49b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-10.82
Gross Margin29.30%
Net Profit Margin-0.59%
Debt/Equity Ratio3.7%

How did A082270 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is A082270 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A082270?

Other financial metrics that can be useful for relative valuation.

A082270 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.7x
Enterprise Value/EBITDA295.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does A082270's PS Ratio compare to its peers?

A082270 PS Ratio vs Peers
The above table shows the PS ratio for A082270 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.3x
A272290 INNOX Advanced MaterialsLtd
A183300 KoMiCo
A084370 Eugene TechnologyLtd
A082270 GemVax&KAELLtd

Price-To-Sales vs Peers: A082270 is expensive based on its Price-To-Sales Ratio (6.9x) compared to the peer average (1.3x).

Price to Earnings Ratio vs Industry

How does A082270's PE Ratio compare vs other companies in the KR Semiconductor Industry?

Price-To-Sales vs Industry: A082270 is expensive based on its Price-To-Sales Ratio (6.9x) compared to the KR Semiconductor industry average (1.1x)

Price to Sales Ratio vs Fair Ratio

What is A082270's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A082270 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A082270's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of A082270 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A082270's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A082270's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is GemVax&KAELLtd forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Semiconductors industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GemVax&KAELLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine GemVax&KAELLtd's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has GemVax&KAELLtd performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A082270 is currently unprofitable.

Growing Profit Margin: A082270 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: A082270 is unprofitable, but has reduced losses over the past 5 years at a rate of 18.7% per year.

Accelerating Growth: Unable to compare A082270's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A082270 is unprofitable, making it difficult to compare its past year earnings growth to the Semiconductor industry (46.7%).

Return on Equity

High ROE: A082270 has a negative Return on Equity (-0.29%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is GemVax&KAELLtd's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: A082270's short term assets (₩46.4B) exceed its short term liabilities (₩15.5B).

Long Term Liabilities: A082270's short term assets (₩46.4B) exceed its long term liabilities (₩2.5B).

Debt to Equity History and Analysis

Debt Level: A082270 has more cash than its total debt.

Reducing Debt: A082270's debt to equity ratio has reduced from 56.7% to 3.7% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if A082270 has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if A082270 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies


What is GemVax&KAELLtd current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

GemVax&KAELLtd Dividend Yield vs Market
How does GemVax&KAELLtd dividend yield compare to the market?
SegmentDividend Yield
Company (GemVax&KAELLtd)n/a
Market Bottom 25% (KR)1.1%
Market Top 25% (KR)3.6%
Industry Average (Semiconductor)1.8%
Analyst forecast in 3 Years (GemVax&KAELLtd)n/a

Notable Dividend: Unable to evaluate A082270's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A082270's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A082270's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A082270's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A082270 has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Sang-Jae Kim (56 yo)

no data


Mr. Sang-Jae Kim serves as Chief Executive Officer at GemVax&KAEL Co.,Ltd. He serves as Co-Chief Executive Officer of BIOVILL Co.,Ltd. (formerly known as KSCB Co.,Ltd.) Mr. Kim serves as the Chief Executiv...


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of A082270?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,677,6764.3%
Public Companies1,937,9294.9%
Private Companies4,763,51112.1%
General Public28,702,27273.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 20 shareholders own 26.85% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
4,504,616₩57.2b0%no data
Sang-Jae Kim
1,115,052₩14.2b0%no data
The Vanguard Group, Inc.
1,107,511₩14.1b1.05%no data
970,145₩12.3b0%no data
Flask Co., Ltd.
967,784₩12.3b0%no data
BlackRock, Inc.
545,582₩6.9b0.46%no data
Creas F&C Invest Co.,Ltd
258,895₩3.3b13.01%no data
Ki-Woong Kim
253,962₩3.2b0.4%no data
Norges Bank Investment Management
237,976₩3.0b0%no data
Woo-Jin Kim
169,963₩2.2b0%no data
Dimensional Fund Advisors LP
113,532₩1.4b7.63%no data
Charles Schwab Investment Management, Inc.
62,963₩799.6m0%no data
Ki-Ho Kim
52,624₩668.3m0%no data
Young-Un Seo
50,000₩635.0m0%no data
Teachers Insurance and Annuity Association-College Retirement Equities Fund
38,019₩482.8m17.9%no data
Hyunggon Song
36,075₩458.2m0%no data
State Street Global Advisors, Inc.
25,871₩328.6m0.68%no data
Geode Capital Management, LLC
21,663₩275.1m-0.04%no data
Northern Trust Global Investments
920₩11.7m0%no data
American Century Investment Management Inc
680₩8.6m0%no data

Company Information

GemVax&KAEL Co.,Ltd's employee growth, exchange listings and data sources

Key Information

  • Name: GemVax&KAEL Co.,Ltd
  • Ticker: A082270
  • Exchange: KOSDAQ
  • Founded: 1998
  • Industry: Semiconductor Equipment
  • Sector: Semiconductors
  • Implied Market Cap: ₩498.299b
  • Shares outstanding: 39.24m
  • Website:

Number of Employees


  • GemVax&KAEL Co.,Ltd
  • 58 Techno 11-ro
  • Yuseong-gu
  • Daejeon
  • South Korea


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
A082270KOSDAQ (KOSDAQ)YesCommon StockKRKRWJun 2005

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/04 00:00
End of Day Share Price2022/10/04 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.